



- (51) **International Patent Classification:**  
*C07K 16/24* (2006.01) *A61P 9/10* (2006.01)  
*C07K 16/18* (2006.01)
- (21) **International Application Number:**  
PCT/NL2015/050860
- (22) **International Filing Date:**  
11 December 2015 (11.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
PCT/NL2014/050859  
12 December 2014 (12.12.2014) NL  
15172609.8 17 June 2015 (17.06.2015) EP
- (71) **Applicant:** UMC UTRECHT HOLDING B.V. [NL/NL];  
Yalelaan 40, 3584 CM Utrecht (NL).
- (72) **Inventor:** ARSLAN, Fatih; c/o Yalelaan 40, 3584 CM  
Utrecht (NL).
- (74) **Agents:** JANSEN, C.M. et al.; V.O., Carnegieplein 5,  
2517 KJ Den Haag (NL).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title:** IMMUNOGLOBULIN-LIKE MOLECULES DIRECTED AGAINST FIBRONECTIN-EDA

(57) **Abstract:** The present invention is concerned with immunoglobulin (Ig)-like molecules or fragments thereof for use in treatment, prevention, or prevention of progression of adverse cardiac remodelling and conditions resulting from or relating to pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury. The invention also provides nucleic acid molecules encoding said Ig-like molecules, vectors comprising same, and host cells comprising same.



WO 2016/093700 A2